NCT05841342招募中不适用
A Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors for Chronic Active Epstein-Barr Virus Infection and Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 128
- 试验地点
- 1
- 主要终点
- EBV-DNA
研究概览
简要总结
This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis by detecting lymphocyte subsets proportions in peripheral blood mononuclear cells and the positive proportion of PD-1, PD-L1 and other indicators in each lymphocyte subsets in healthy people and patients using flow cytometry before and after the initial PD-1 therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 2 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients who meet the diagnostic criteria of EBV-HLH or CAEBV (except B lymphocytes involvement only) after the detection of EBV lymphocyte subsets. EBV-HLH diagnostic criteria: Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria; EBV-DNA in peripheral blood or EBER in tissue were positive, patients were diagnosed with EBV associated HLH (EBV-HLH). CAEBV diagnostic criteria: (1) persistent or recurrent infectious mononucleosis-like symptoms persisting for more than 3 months; (2) EBV-DNA quantitative increase in peripheral blood or tissue lesions; (3) exclusion of other possible Diagnosis, such as primary Epstein-Barr virus infection (infectious mononucleosis), autoimmune disease, congenital immunodeficiency, human immunodeficiency virus (HIV) infection, or other underlying conditions requiring immunosuppressive therapy or underlying immunosuppression.
- •Before the start of the study, total bilirubin ≤10 times the upper limit of normal, serum creatinine ≤1.5 times the normal value; fibrinogen can be corrected to ≥0.6g/L after infusion.
- •Serum HIV antigen or antibody negative.
- •HCV antibody negative, or HCV antibody positive, but HCV RNA negative.
- •HBV surface antigen and HBV core antibody are both negative. If any of the above is positive, peripheral blood hepatitis B virus DNA titer detection is required, and the number of copies less than 1×103 copies/ml can be included in the group.
- •LVEF ≥ 50% by cardiac echocardiography.
- •Women of childbearing age must be confirmed by a pregnancy test that they are not pregnant, and are willing to take effective contraceptive measures during the test period and within ≥ 12 months after the last dose. Women during pregnancy and lactation cannot participate. Contraceptive measures should be taken during the test period and within ≥3 months after the last dose.
- •Informed consent obtained.
排除标准
- •According to the New York Heart Association (NYHA) score, patients with heart disease of grade II or above (including grade II);
- •Pregnant or lactating women and patients of childbearing age who refused to take appropriate contraceptive measures during this trial.
- •Those who are allergic to rituximab ingredients or have more severe allergic constitution;
- •Severe hypogammaglobulinemia.
- •Active massive hemorrhage of internal organs (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.);
- •Uncontrolled active infection (including lung infection, intestinal infection, etc.);
- •HBV surface antigen and/or HBV core antibody are positive, and the peripheral blood hepatitis B virus DNA test confirms the existence of active hepatitis B patients.
- •Severe mental illness;
- •Patients who were not compliant during the trial and/or follow-up period.
- •Concurrently participate in other clinical investigators.
结局指标
主要结局
EBV-DNA
时间窗: Change from before and 2 weeks after initiating PD-1 blockade therapy.
Treatment effectiveness is defined: EBV-DNA copies/ml in peripheral blood turns negative, and the involved tissues (such as lymph nodes, bone marrow, skin, etc.) are negative in EBER test or the EBV copy number has decreased by more than 2 orders of magnitude, but it is still positive.
次要结局
- CAEBV Evaluation of treatment response(Change from before and 2 weeks after initiating PD-1 blockade therapy.)
- Progression Free Survival(6 months)
- EBV-HLH Evaluation of treatment response(Change from before and 2 weeks after initiating PD-1 blockade therapy.)
研究者
Zhao Wang
Clinical Professor
Beijing Friendship Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
The Immune Assessment of PD-1 Antibody Therapy in TumorEfficacy, TeamAdverse EventNCT06693440Quanli Gao3,000
Unknown
不适用
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyCarcinoma, Non-Small-Cell LungImmune-Related Adverse EventsNCT04115410Sungkyunkwan University4,724
已完成
不适用
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC PatientsNon -Small Cell Lung CancerNCT03486119Yonsei University60
已完成
不适用
A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC PatientsNon Small Cell Lung CancerNCT04312308Yonsei University100
进行中（未招募）
2 期
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersBronchial DysplasiaTobacco SmokingHistory of Non-Small Cell Lung CancerHistory of Head and Neck CancerNCT03347838University of Colorado, Denver19